BRISTOL-MYERS SQUIBB CO (BRM.DE) Stock Fundamental Analysis
Europe - FRA:BRM - US1101221083 - Common Stock
38.835 EUR
+0.02 (+0.05%)
Taking everything into account, BRM scores 6 out of 10 in our fundamental rating. BRM was compared to 51 industry peers in the Pharmaceuticals industry. BRM has only an average score on both its financial health and profitability. BRM scores decently on growth, while it is valued quite cheap. This could make an interesting combination. Finally BRM also has an excellent dividend rating. This makes BRM very considerable for value and dividend investing!
1. Profitability
1.1 Basic Checks
In the past year BRM was profitable.
In the past year BRM had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: BRM reported negative net income in multiple years.
In the past 5 years BRM always reported a positive cash flow from operatings.
1.2 Ratios
BRM has a Return On Assets of 5.33%. This is comparable to the rest of the industry: BRM outperforms 52.94% of its industry peers.
With an excellent Return On Equity value of 28.96%, BRM belongs to the best of the industry, outperforming 82.35% of the companies in the same industry.
BRM has a Return On Invested Capital of 15.09%. This is amongst the best in the industry. BRM outperforms 80.39% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BRM is below the industry average of 15.09%.
The 3 year average ROIC (10.96%) for BRM is below the current ROIC(15.09%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.33% | ||
| ROE | 28.96% | ||
| ROIC | 15.09% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
1.3 Margins
The Profit Margin of BRM (10.58%) is comparable to the rest of the industry.
BRM has a better Operating Margin (30.27%) than 80.39% of its industry peers.
BRM's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 73.92%, BRM is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
BRM's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.27% | ||
| PM (TTM) | 10.58% | ||
| GM | 73.92% |
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BRM is creating value.
Compared to 1 year ago, BRM has less shares outstanding
Compared to 5 years ago, BRM has less shares outstanding
The debt/assets ratio for BRM is higher compared to a year ago.
2.2 Solvency
BRM has an Altman-Z score of 2.04. This is not the best score and indicates that BRM is in the grey zone with still only limited risk for bankruptcy at the moment.
BRM's Altman-Z score of 2.04 is on the low side compared to the rest of the industry. BRM is outperformed by 62.75% of its industry peers.
The Debt to FCF ratio of BRM is 3.37, which is a good value as it means it would take BRM, 3.37 years of fcf income to pay off all of its debts.
BRM has a Debt to FCF ratio of 3.37. This is in the better half of the industry: BRM outperforms 60.78% of its industry peers.
A Debt/Equity ratio of 2.56 is on the high side and indicates that BRM has dependencies on debt financing.
BRM has a Debt to Equity ratio of 2.56. This is amonst the worse of the industry: BRM underperforms 80.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.56 | ||
| Debt/FCF | 3.37 | ||
| Altman-Z | 2.04 |
ROIC/WACC1.97
WACC7.65%
2.3 Liquidity
A Current Ratio of 1.21 indicates that BRM should not have too much problems paying its short term obligations.
With a Current ratio value of 1.21, BRM perfoms like the industry average, outperforming 41.18% of the companies in the same industry.
BRM has a Quick Ratio of 1.11. This is a normal value and indicates that BRM is financially healthy and should not expect problems in meeting its short term obligations.
BRM has a better Quick ratio (1.11) than 70.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.11 |
3. Growth
3.1 Past
BRM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 391.24%, which is quite impressive.
BRM shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -24.57% yearly.
The Revenue has been growing slightly by 2.57% in the past year.
The Revenue has been growing by 13.06% on average over the past years. This is quite good.
EPS 1Y (TTM)391.24%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-29.47%
Revenue 1Y (TTM)2.57%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%0.56%
3.2 Future
Based on estimates for the next years, BRM will show a very strong growth in Earnings Per Share. The EPS will grow by 36.11% on average per year.
BRM is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -4.99% yearly.
EPS Next Y477.64%
EPS Next 2Y131.04%
EPS Next 3Y73.61%
EPS Next 5Y36.11%
Revenue Next Year-1.12%
Revenue Next 2Y-4.71%
Revenue Next 3Y-3.48%
Revenue Next 5Y-4.99%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 6.77, the valuation of BRM can be described as very cheap.
Compared to the rest of the industry, the Price/Earnings ratio of BRM indicates a rather cheap valuation: BRM is cheaper than 94.12% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.86. BRM is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 7.49, which indicates a rather cheap valuation of BRM.
Based on the Price/Forward Earnings ratio, BRM is valued cheaper than 92.16% of the companies in the same industry.
BRM is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.32, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.77 | ||
| Fwd PE | 7.49 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BRM is valued cheaply inside the industry as 92.16% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, BRM is valued cheaply inside the industry as 96.08% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.36 | ||
| EV/EBITDA | 6.07 |
4.3 Compensation for Growth
BRM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of BRM may justify a higher PE ratio.
BRM's earnings are expected to grow with 73.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y131.04%
EPS Next 3Y73.61%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 5.42%, BRM is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 3.01, BRM pays a better dividend. On top of this BRM pays more dividend than 92.16% of the companies listed in the same industry.
BRM's Dividend Yield is rather good when compared to the S&P500 average which is at 2.44.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.42% |
5.2 History
The dividend of BRM is nicely growing with an annual growth rate of 11.67%!
Dividend Growth(5Y)11.67%
Div Incr Years3
Div Non Decr Years3
5.3 Sustainability
BRM pays out 98.12% of its income as dividend. This is not a sustainable payout ratio.
The dividend of BRM is growing, but earnings are growing more, so the dividend growth is sustainable.
DP98.12%
EPS Next 2Y131.04%
EPS Next 3Y73.61%
FRA:BRM (10/6/2025, 2:30:41 PM)
38.835
+0.02 (+0.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners82.84%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap79.05B
Analysts67.27
Price Target44.24 (13.92%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.42% |
Yearly Dividend2.06
Dividend Growth(5Y)11.67%
DP98.12%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.2%
Min EPS beat(2)19.36%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)21.86%
Min EPS beat(4)13.54%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)17.22%
EPS beat(12)11
Avg EPS beat(12)11.73%
EPS beat(16)15
Avg EPS beat(16)9.9%
Revenue beat(2)2
Avg Revenue beat(2)5.24%
Min Revenue beat(2)3.68%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)5.13%
Min Revenue beat(4)3.68%
Max Revenue beat(4)6.79%
Revenue beat(8)7
Avg Revenue beat(8)3.53%
Revenue beat(12)8
Avg Revenue beat(12)1.72%
Revenue beat(16)10
Avg Revenue beat(16)1.44%
PT rev (1m)-2.11%
PT rev (3m)-9.39%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.32%
EPS NY rev (1m)0.08%
EPS NY rev (3m)-3.59%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.93%
Revenue NY rev (1m)0.15%
Revenue NY rev (3m)2.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.77 | ||
| Fwd PE | 7.49 | ||
| P/S | 1.94 | ||
| P/FCF | 6.36 | ||
| P/OCF | 5.83 | ||
| P/B | 5.32 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.07 |
EPS(TTM)5.74
EY14.78%
EPS(NY)5.19
Fwd EY13.35%
FCF(TTM)6.1
FCFY15.72%
OCF(TTM)6.66
OCFY17.14%
SpS19.97
BVpS7.3
TBVpS-10.77
PEG (NY)0.01
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.33% | ||
| ROE | 28.96% | ||
| ROCE | 21.51% | ||
| ROIC | 15.09% | ||
| ROICexc | 18.9% | ||
| ROICexgc | 95.64% | ||
| OM | 30.27% | ||
| PM (TTM) | 10.58% | ||
| GM | 73.92% | ||
| FCFM | 30.56% |
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)10.96%
ROIC(5y)9.23%
ROICexc(3y)12.89%
ROICexc(5y)10.99%
ROICexgc(3y)70.36%
ROICexgc(5y)72.03%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexcg growth 3Y-16.88%
ROICexcg growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score7
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.56 | ||
| Debt/FCF | 3.37 | ||
| Debt/EBITDA | 2.14 | ||
| Cap/Depr | 20.37% | ||
| Cap/Sales | 2.77% | ||
| Interest Coverage | 6.99 | ||
| Cash Conversion | 75.95% | ||
| Profit Quality | 288.73% | ||
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.11 | ||
| Altman-Z | 2.04 |
F-Score7
WACC7.65%
ROIC/WACC1.97
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)391.24%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-29.47%
EPS Next Y477.64%
EPS Next 2Y131.04%
EPS Next 3Y73.61%
EPS Next 5Y36.11%
Revenue 1Y (TTM)2.57%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%0.56%
Revenue Next Year-1.12%
Revenue Next 2Y-4.71%
Revenue Next 3Y-3.48%
Revenue Next 5Y-4.99%
EBIT growth 1Y30.41%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year263.82%
EBIT Next 3Y49.42%
EBIT Next 5Y23.71%
FCF growth 1Y35.99%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y34.19%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%